ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an ...
Bio-Techne develops, manufactures and sells life science reagents, instruments and services for the research, pharmaceutical, diagnostics and bioprocessing markets worldwide. In 2013, Bio-Techne ...
The Graduate Architecture, Urban Design, and Landscape Architecture programs (GA/LA/UD) at Pratt Institute are proud to participate in the Biodesign Challenge (BDC) with their project submission ...
Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...
Fintel reports that on November 20, 2025, Argus Research maintained coverage of Bio-Techne (NasdaqGS:TECH) with a Buy recommendation. As of November 17, 2025, the average one-year price target for Bio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback